Armata links bacteria-killing virus to clinical responses in phase 2 trial
Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage cocktail to improved outcomes in patients with bacteria in their blood, opening the door to further study of a modality that could address the limitations of antibiotics.
Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage cocktail to improved outcomes in patients with bacteria in their blood, opening the door to further study of a modality that could address the limitations of antibiotics.
